Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

Review Decision - January 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 89 KB)

Review Proposal - August 2009 information

Appendix A: provisional matrix of stakeholders (PDF 34 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 79 KB)

Colorectal cancer (metastatic) - bevacizumab & cetuximab: appeal information

Appeal announcement: Bevacizumab and cetuximab for metastatic colorectal cancer information

Appeal received from Merck Pharmaceuticals

Initial scrutiny letter (PDF 103 KB)

Merck Pharmaceuticals response to the scrutiny letter (PDF 127 KB)

Appeals received

Merck Pharmaceuticals 1 (PDF 48 KB)

Merck Pharmaceuticals 2 (PDF 938 KB)

Appeal received from Bowel Cancer UK and Cancerbackup (joint appeal)

Appeals received (PDF 41 KB)

Initial scrutiny letter (PDF 96 KB)

Bowel Cancer UK & Cancerbackup's response to the scrutiny letter (PDF 72 KB)

Final Scrutiny letter (PDF 43 KB)

Colorectal cancer (metastatic) - bevacizumab & cetuximab: Appeal panel decision (PDF 43 KB)

Colorectal cancer (metastatic) - bevacizumab & cetuximab - Final appraisal determination information

Final appraisal determination (PDF 174 KB)

Response to consultee and commentator comments and response to public and web comments on the ACD (PDF 244 KB)

Consultee and commentator comments on the ACD

Royal College of Physicians (PDF 46 KB)

Royal College of Pathologists (PDF 71 KB)

Royal College of Nursing (PDF 28 KB)

Roche Products Ltd (PDF 129 KB)

NHS Quality Improvement Scotland (PDF 28 KB)

Merck Pharmaceuticals (PDF 163 KB)

Cancer Backup (PDF 22 KB)

Bowel Cancer UK (PDF 23 KB)

Anthoney (PDF 21 KB)

Colorectal cancer (advanced) - bevacizumab & cetuximab (appraisal consultation document) information

Overview (PDF 140 KB)

Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report (PDF 1.11 MB)

Consultee and commentator comments on the assessment report

Bowel Cancer UK (PDF 72 KB)

Merck Pharmaceuticals (PDF 582 KB)

NHS Quality Improvement Scotland (PDF 31 KB)

Roche (PDF 320 KB)

Royal College of Nursing (PDF 108 KB)

Royal College of Pathologists (PDF 72 KB)

Non-manufacturer submissions

Association of Coloproctologists of Great Britain (PDF 326 KB)

Beating Bowel Cancer (PDF 511 KB)

Bowel Cancer UK (formerly known as Colon Cancer Concern) (PDF 2.02 MB)

Cancerbackup (PDF 252 KB)

Royal College of Nursing (PDF 193 KB)

Royal College of Pathologists (PDF 46 KB)

Royal College of Physicians (support letter) (PDF 41 KB)

ScHARR (PDF 349 KB)

Manufacturer submissions

Roche (PDF 271 KB)

Merck (PDF 191 KB)

Expert written personal statements

Anthoney (PDF 348 KB)

Rhys Evans (PDF 217 KB)

Smith (PDF 215 KB)

Final protocol (PDF 208 KB)

Summary of comments on the draft scope (PDF 47 KB)

Final scope (PDF 26 KB)

Archive: Draft scope (PDF 26 KB)

Summary of comments on the provisional matrix of consultees and commentators (PDF 20 KB)

Archive: Provisional matrix of consultees and commentators (PDF 29 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information